

# Financial Tear Sheet

## Corporate Profile

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid's drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in people with Angelman syndrome and completed a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.

## Stock Performance

### OVID (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	<b>\$9.72</b>
Change (%)	<b>▼ 0.67 (6.45%)</b>
Volume	192,219
52 Week High	\$15.93
52 Week Low	\$5.28
Market Cap	\$239,143,989
Rolling EPS	-2.65
PE Ratio	0
Shares Outstanding	24,603,291

Data as of December 15, 2017 4:00 p.m. ET



## Recent Headlines

December 5, 2017

Ovid Therapeutics Announces TAK-935/OV935 Has Received Orphan Drug Designation from U.S. FDA for Treatment of Dravet Syndrome

---

December 3, 2017

Ovid Therapeutics Presents New Data Demonstrating Potential of TAK-935/OV935 as a Novel Treatment for Developmental and Epileptic Encephalopathies at the American Epilepsy Society (AES) Annual Meeting

---

November 28, 2017

Ovid Therapeutics Announces OV101 Shows Comparable PK Profile in Phase 1 Study of Adolescent Patients and Amends Phase 2 STARS Clinical Trial Protocol to Include Adolescents

---

## Upcoming Events

There are currently no events scheduled.

## SEC Filings

Filing Date	Form
December 11, 2017	8-K
December 4, 2017	8-K
November 9, 2017	10-Q
November 9, 2017	8-K

---

## Corporate Governance

Jeremy Levin, D.Phil., MB BChir	Chairman of the Board of Directors
------------------------------------	--

---

Data provided by Nasdaq. Minimum 15 minutes delayed.

© Ovid Therapeutics.. All rights reserved.